Amgen Inc. Contracts & Agreements

Form of Grant of Stock Option Agreement for the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (Filed With SEC on August 7, 2024)

Form of Restricted Stock Unit Agreement for the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (Filed With SEC on August 7, 2024)

Amgen Inc. 2009 Performance Award Program (Filed With SEC on August 7, 2024)

Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program (Filed With SEC on August 7, 2024)

Amgen Inc. 2009 Director Equity Incentive Program (Filed With SEC on August 7, 2024)

Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program (Filed With SEC on August 7, 2024)

Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program (Filed With SEC on August 7, 2024)

Description of Amgen Inc.s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 14, 2024)

Form of Grant of Stock Option Agreement for the Amgen Inc (Filed With SEC on February 14, 2024)

Form of Restricted Stock Unit Agreement (Filed With SEC on February 14, 2024)

Form of Performance Unit Agreement (Filed With SEC on February 14, 2024)

Amgen Inc. 2009 Director Equity Incentive Program. (As Amended and Restated on October 24, 2023.) (Filed With SEC on February 14, 2024)

Fifth Amendment to the Amgen Inc. Supplemental Retirement Plan, effective January 1, 2024 (Filed With SEC on February 14, 2024)

Fourth Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2024 (Filed With SEC on February 14, 2024)

Agreement between Amgen Inc. and James Bradner, dated December 13, 2023 (Filed With SEC on February 14, 2024)

Second Amendment to Collaboration Agreement, entered into as of February 26, 2023, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd (Filed With SEC on April 28, 2023)

Third Amended and Restated Credit Agreement, dated as of March 9, 2023, among Amgen Inc., the Banks therein named, Citibank, N.A., as Administrative Agent, and JPMorgan Chase... (Filed With SEC on March 9, 2023)

Officers Certificate of the Company, dated as of March 2, 2023, including forms of the Companys 5.250% Senior Notes due 2025, 5.507% Senior Notes due 2026, 5.150% Senior Notes due... (Filed With SEC on March 2, 2023)

Underwriting Agreement, dated February 15, 2023, by and among the Company and Citigroup Global Markets Inc., BofA Securities, Inc., Goldman Sachs & Co. LLC and Mizuho Securities... (Filed With SEC on February 16, 2023)

Description of Amgen Inc.s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 9, 2023)

Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan (Filed With SEC on February 9, 2023)

Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan (Filed With SEC on February 9, 2023)

Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program (Filed With SEC on February 9, 2023)

Fourth Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2022 (Filed With SEC on February 9, 2023)

Amendment No. 3 to Share Purchase Agreement, dated January 30, 2023, by and among BeiGene, Ltd. and Amgen Inc (Filed With SEC on January 31, 2023)

Term Loan Credit Agreement, dated as of December 22, 2022, by and among Amgen Inc., Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank,... (Filed With SEC on December 22, 2022)

Transaction Agreement, dated as of December 11, 2022, by and among Amgen Inc., Pillartree Limited and Horizon Therapeutics plc (Filed With SEC on December 12, 2022)

Appendix 3 to the Rule 2.7 Announcement, dated as of December 12, 2022 (Conditions Appendix) (Filed With SEC on December 12, 2022)

Bridge Credit Agreement, dated as of December 12, 2022, by and among Amgen Inc., Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank,... (Filed With SEC on December 12, 2022)

Amendment No. 1 to Sourcing and Supply Agreement, dated July 14, 2022, by and between Amgen USA Inc., a wholly owned subsidiary of Amgen Inc., and DaVita Inc (Filed With SEC on November 4, 2022)

Underwriting Agreement, dated August 15, 2022, by and among the Company and BofA Securities, Inc., Morgan Stanley & Co. LLC, Credit Suisse Securities (USA) LLC and Deutsche Bank... (Filed With SEC on August 18, 2022)

Officers Certificate of the Company, dated as of August 18, 2022, including forms of the Companys 4.050% Senior Notes due 2029, 4.200% Senior Notes due 2033 and 4.875% Senior... (Filed With SEC on August 18, 2022)

First Amendment to Collaboration Agreement, dated April 20, 2022, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd (Filed With SEC on August 5, 2022)

Agreement and Plan of Merger, dated as of August 3, 2022 among ChemoCentryx, Inc., Amgen Inc. and Carnation Merger Sub, Inc (Filed With SEC on August 4, 2022)

Amgen Inc. Executive Incentive Plan (Filed With SEC on April 28, 2022)

Form of ASR Agreement (Filed With SEC on February 25, 2022)

Underwriting Agreement, dated February 17, 2022, by and among the Company and BofA Securities, Inc., Morgan Stanley & Co. LLC, Citigroup Global Markets Inc. and Goldman Sachs &... (Filed With SEC on February 22, 2022)

Officers Certificate of the Company, dated as of February 22, 2022, including forms of the Companys 3.000% Senior Notes due 2029, 3.350% Senior Notes due 2032, 4.200% Senior Notes... (Filed With SEC on February 22, 2022)

Description of Amgen Inc.s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 16, 2022)

Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended (Filed With SEC on February 16, 2022)

Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended (Filed With SEC on February 16, 2022)

Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended (Filed With SEC on February 16, 2022)

Third Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2021 (Filed With SEC on February 16, 2022)

Third Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2022 (Filed With SEC on February 16, 2022)

Aircraft Time Sharing Agreement, dated December 3, 2021, by and between Amgen Inc. and Robert A. Bradway (Filed With SEC on February 16, 2022)

Amendment No. 8 to the Collaboration Agreement, dated November 19, 2021, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC (Filed With SEC on February 16, 2022)

Amendment No. 3 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been... (Filed With SEC on January 31, 2022)

Agreement and Plan of Merger, dated July 27, 2021, by and among Amgen Inc., Teneobio, Inc., Tuxedo Merger Sub, Inc., and Fortis Advisors LLC (Filed With SEC on November 3, 2021)

Underwriting Agreement, dated August 5, 2021, by and among the Company and Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, Barclays Capital Inc. and Goldman Sachs & Co.... (Filed With SEC on August 9, 2021)

Officers Certificate of the Company, dated as of August 9, 2021, including forms of the Companys 1.650% Senior Notes due 2028, 2.000% Senior Notes due 2032, 2.800% Senior Notes... (Filed With SEC on August 9, 2021)

Amended and Restated Collaboration Agreement, dated June 2, 2021, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on August 4, 2021)

Agreement and Plan of Merger, dated as of March 4, 2021, by and among Amgen Inc., Franklin Acquisition Sub, Inc. and Five Prime Therapeutics, Inc (Filed With SEC on March 4, 2021)

Description of Amgen Inc.s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 9, 2021)

Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 1 (Filed With SEC on February 9, 2021)

Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December (Filed With SEC on February 9, 2021)

Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on December 1 (Filed With SEC on February 9, 2021)

Amgen Inc. 2009 Director Equity Incentive Program. (As Amended (Filed With SEC on February 9, 2021)

Amendment No. 7 to the Collaboration Agreement, dated December 18, 2020, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC (Filed With SEC on February 9, 2021)

Amendment No. 2 to the Collaboration Agreement, dated August 19, 2020, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on October 29, 2020)

Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc (Filed With SEC on October 29, 2020)

Officers Certificate of Amgen Inc., dated as of August 17, 2020, including forms of the Companys 2.770% Senior Notes due 2053 (Filed With SEC on August 18, 2020)

Registration Rights Agreement, dated as of August 17, 2020, by and among the Company, BofA Securities, Inc. and J.P. Morgan Securities LLC, as lead dealer managers, and BNP... (Filed With SEC on August 18, 2020)

Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016,... (Filed With SEC on July 29, 2020)

Underwriting Agreement, dated as of May 4, 2020, by and among the Company and BofA Securities, Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Morgan Stanley &... (Filed With SEC on May 6, 2020)

Officers Certificate of the Company, dated as of May 6, 2020, including the form of the Companys 2.300% Senior Notes due 2031 (Filed With SEC on May 6, 2020)

Agreement between Amgen Inc. and Peter Griffith, dated October 18, 2019 (Filed With SEC on May 1, 2020)

Side Letter Regarding Collaboration Agreement and Stivarga Agreement, dated February 13, 2020, by and between Onyx Pharmaceuticals, Inc. and Bayer HealthCare LLC (Filed With SEC on May 1, 2020)

Amendment No. 2 to Share Purchase Agreement, dated March 17, 2020, by and among BeiGene, Ltd. and Amgen Inc (Filed With SEC on May 1, 2020)

Underwriting Agreement, dated February 18, 2020, by and among the Company and Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Barclays Capital Inc. and Morgan Stanley &... (Filed With SEC on February 21, 2020)

Officers Certificate of the Company, dated as of February 21, 2020, including forms of the Companys 1.900% Senior Notes due 2025, 2.200% Senior Notes due 2027, 2.450% Senior Notes... (Filed With SEC on February 21, 2020)

Amendment No. 2 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation (Filed With SEC on February 12, 2020)

Description of Amgen Inc.s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 12, 2020)

Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 10, 2019.) (Filed With SEC on February 12, 2020)

Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 10, 2019.) (Filed With SEC on February 12, 2020)

Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on December 10, 2019.) (Filed With SEC on February 12, 2020)

Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed With SEC on February 12, 2020)

Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed With SEC on February 12, 2020)

Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed With SEC on February 12, 2020)

Second Amendment to the Amgen Inc. Supplemental Retirement Plan (As Amended and Restated effective October 23, 2019) (Filed With SEC on February 12, 2020)

Second Amendment to the Amgen Nonqualified Deferred Compensation Plan (As Amended and Restated effective January 1, 2020) (Filed With SEC on February 12, 2020)

Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc (Filed With SEC on February 12, 2020)

Letter Agreement, dated November 21, 2019, by and between Amgen Inc. and the parties named therein re: Treatment of Certain Product Inventory in connection with Amgens acquisition... (Filed With SEC on February 12, 2020)

Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd (Filed With SEC on February 12, 2020)

Second Amended and Restated Credit Agreement, dated as of December 12, 2019, among Amgen Inc., the Banks therein named, Citibank, N.A., as Administrative Agent, and JPMorgan Chase... (Filed With SEC on December 12, 2019)

Amendment No. 1 to the Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation (Filed With SEC on October 18, 2019)

Irrevocable Guarantee, dated August 25, 2019, by and between Amgen Inc. and Bristol-Myers Squibb Company (Filed With SEC on August 26, 2019)

Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation (Filed With SEC on August 26, 2019)

Letter Agreement, dated June 25, 2019, by and between Amgen Inc. and UCB Celltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would... (Filed With SEC on July 31, 2019)

Form of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 7, 2018.) (Filed With SEC on February 13, 2019)

Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 7, 2018.) (Filed With SEC on February 13, 2019)

Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on December 7, 2018.) (Filed With SEC on February 13, 2019)

Agreement between Amgen Inc. and Murdo Gordon, dated July 25, 2018 (Filed With SEC on October 31, 2018)

Amendment No. 1 to the Credit Agreement, dated March 9, 2018, among Amgen Inc., the Banks therein named, and Citibank, N.A., as administrative agent (Filed With SEC on April 25, 2018)

Amendment No. 1 to the Collaboration Agreement, dated March 20, 2018, by and between Novartis Pharma AG and Amgen Inc. (portions of the exhibit have been omitted pursuant to a... (Filed With SEC on April 25, 2018)

Form of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 12, 2017.) (Filed With SEC on February 13, 2018)

Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 12, 2017.) (Filed With SEC on February 13, 2018)

Amgen Inc. 2009 Performance Award Program. (As Amended on December 12, 2017.) (Filed With SEC on February 13, 2018)

Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on December 12, 2017.) (Filed With SEC on February 13, 2018)

Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on October 24, 2017.) (Filed With SEC on February 13, 2018)

Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on October 24, 2017.) (Filed With SEC on February 13, 2018)

Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen 2009 Director Equity Incentive Program (Filed With SEC on February 13, 2018)

Underwriting Agreement, dated October 31, 2017, by and among the Company and J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BNP Paribas Securities Corp., as... (Filed With SEC on November 2, 2017)

Officers Certificate of the Company, dated as of November 2, 2017, including the form of the Companys 3.200% Senior Notes due 2027 (Filed With SEC on November 2, 2017)

Exclusive License and Collaboration Agreement, dated August 28, 2015, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on July 26, 2017)

Amendment No. 1 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on July 26, 2017)

Amendment No. 2 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on July 26, 2017)

Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on July 26, 2017)

AMGEN INC. $300,000,000SENIOR FLOATING RATE NOTES DUE 2019 $300,000,000 SENIOR FLOATING RATE NOTES DUE 2020 $700,000,000 1.900% SENIOR NOTES DUE 2019 $700,000,000 2.200% SENIOR... (Filed With SEC on May 11, 2017)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on May 11, 2017)

Second Amendment to the Amgen Inc. Executive Incentive Plan, effective January 1, 2017 (Filed With SEC on April 27, 2017)

Form of Award Notice (Filed With SEC on February 14, 2017)

Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange... (Filed With SEC on February 14, 2017)

FIRST AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013 (Filed With SEC on October 28, 2016)

FIRST AMENDMENT TO THE AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013 (Filed With SEC on October 28, 2016)

AMGEN INC. $750,000,0001.850% SENIOR NOTES DUE 2021 $750,000,000 2.250% SENIOR NOTES DUE 2023 $1,250,000,000 2.600% SENIOR NOTES DUE 2026 $1,000,000,000 4.400% SENIOR NOTES DUE... (Filed With SEC on August 19, 2016)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on August 19, 2016)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on June 14, 2016)

REGISTRATION RIGHTS AGREEMENT among AMGEN INC. and CREDIT SUISSE SECURITIES(USA) LLC J.P. MORGAN SECURITIES LLC CITIGROUP GLOBAL MARKETS INC. and MIZUHO SECURITIES USA INC. each... (Filed With SEC on June 14, 2016)

Second Amendment to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, As Amended (Filed With SEC on May 2, 2016)

Form of Award Notice (Filed With SEC on May 2, 2016)

AMGEN INC. 2009 PERFORMANCE AWARD PROGRAM (Effective March 3, 2009) As Amended Through March 2, 2016 ARTICLE I PURPOSE (Filed With SEC on May 2, 2016)

Form of Award Notice (Filed With SEC on May 2, 2016)

Form of Permanent Global Certificate (Globalurkunde auf Dauer) of CHF 700,000,000 (700,000,000 Swiss francs) Amgen Inc. One AmgenCenter Drive Thousand Oaks, California... (Filed With SEC on March 8, 2016)

TERMS AND CONDITIONS (Filed With SEC on March 8, 2016)

AMGENINC. 1,250,000,000 1.250% SENIOR NOTES DUE 2022 750,000,000 2.000% SENIOR NOTES DUE 2026 Underwriting Agreement (Filed With SEC on February 25, 2016)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on February 25, 2016)

Form of Award Notice (Filed With SEC on November 2, 2015)

Form of Award Notice (Filed With SEC on August 5, 2015)

AMGENINC. $750,000,000 2.125% SENIOR NOTES DUE 2020 $500,000,000 2.700% SENIOR NOTES DUE 2022 $1,000,000,000 3.125% SENIOR NOTES DUE 2025 $1,250,000,000 4.400% SENIOR NOTES DUE... (Filed With SEC on May 1, 2015)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on May 1, 2015)

First Amendment to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan (Filed With SEC on April 27, 2015)

Form of Award Notice (Filed With SEC on April 27, 2015)

Form of Award Notice (Filed With SEC on February 19, 2015)

Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange... (Filed With SEC on February 19, 2015)

AMENDED ANDRESTATED CREDIT AGREEMENT Dated as of July 30, 2014 among Amgen Inc., The Borrowing Subsidiaries Herein Named, The Banks Herein Named, Citibank, N.A., asAdministrative... (Filed With SEC on July 30, 2014)

AMGENINC. $850,000,000 1.250% SENIOR NOTES DUE 2017 $1,400,000,000 2.200% SENIOR NOTES DUE 2019 $1,400,000,000 3.625% SENIOR NOTES DUE 2024 $600,000,000 SENIOR FLOATING RATE NOTES... (Filed With SEC on May 22, 2014)

AMGEN INC. INDENTURE Dated as of May 22, 2014 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee TABLE OF CONTENTS (Filed With SEC on May 22, 2014)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on May 22, 2014)

Form of Award Notice (Filed With SEC on April 30, 2014)

AMENDMENT NO. 14 TO THE SHAREHOLDERS AGREEMENT OF KIRIN-AMGEN, INC. (Filed With SEC on April 30, 2014)

AMGEN INC. 2009 PERFORMANCE AWARD PROGRAM (Effective March 3, 2009) As Amended Through December 13, 2013 ARTICLE I PURPOSE (Filed With SEC on February 24, 2014)

AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN (As Amended and Restated Effective October 16, 2013) AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN (As Amended and Restated Effective October 16,... (Filed With SEC on February 24, 2014)

Amgen Nonqualified Deferred Compensation Plan As Amended and Restated Effective October 16, 2013 (Filed With SEC on February 24, 2014)

AGREEMENT AND GENERAL RELEASE OF CLAIMS (Filed With SEC on February 24, 2014)

AMENDMENT NUMBER 5 TO THE INTEGRATED FACILITIES MANAGEMENT SERVICES AGREEMENT BETWEEN JONES LANG LASALLE AMERICAS, INC. AND AMGEN INC. (Filed With SEC on October 29, 2013)

TERM LOAN FACILITY CREDIT AGREEMENT Dated as of September 20, 2013 among AMGEN INC., as the Borrower, BANK OFAMERICA, N.A., as Administrative Agent, The Banks Party Hereto,... (Filed With SEC on September 20, 2013)

AGREEMENT AND PLAN OF MERGER by and among: ONYX PHARMACEUTICALS, INC., a Delaware corporation; AMGEN INC., a Delaware corporation; and ARENA ACQUISITION COMPANY, a Delaware... (Filed With SEC on August 26, 2013)

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED BANK OF AMERICA, N.A. One Bryant Park New York, New York 10036 (Filed With SEC on August 26, 2013)

Form of Award Notice (Filed With SEC on May 3, 2013)

AMGEN INC. 2009 PERFORMANCE AWARD PROGRAM (Effective March 3, 2009) As Amended Through March 6, 2013 ARTICLE I PURPOSE (Filed With SEC on May 3, 2013)

Form of Award Notice (Filed With SEC on May 3, 2013)

AMGEN INC. 2009 DIRECTOR EQUITY INCENTIVE PROGRAM (Effective January 1, 2013) As Amended and Restated December 13, 2012 and Subsequently Amended March 6, 2013 ARTICLE I PURPOSE (Filed With SEC on May 3, 2013)

RESTRICTED STOCK UNIT AGREEMENT (Director Equity Incentive Program) (Filed With SEC on May 3, 2013)

CONSULTING SERVICES AGREEMENT (Filed With SEC on May 3, 2013)

AMENDMENT NUMBER 4 TO THE INTEGRATED FACILITIES MANAGEMENT SERVICES AGREEMENT BETWEEN JONES LANG LASALLE AMERICAS, INC. AND AMGEN INC. (Filed With SEC on May 3, 2013)

AMGEN INC. 2009 PERFORMANCE AWARD PROGRAM (Effective March 3, 2009) As Amended December 13, 2012 ARTICLE I PURPOSE (Filed With SEC on February 27, 2013)

AMGEN INC. 2009 DIRECTOR EQUITY INCENTIVE PROGRAM (Effective January 1, 2013) As Amended and Restated December 13, 2012 ARTICLE I PURPOSE (Filed With SEC on February 27, 2013)

RESTRICTED STOCK UNIT AGREEMENT (Director Equity Incentive Program) (Filed With SEC on February 27, 2013)

FIRST AMENDMENT TO THE AMGEN INC. EXECUTIVE INCENTIVE PLAN (AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009) (Filed With SEC on February 27, 2013)

AMENDMENT NO. 1 TO THE LICENSE AGREEMENT (Filed With SEC on February 27, 2013)

AMENDMENT NO. 2 TO THE LICENSE AGREEMENT (Filed With SEC on February 27, 2013)

GRANT AGREEMENT (Filed With SEC on December 7, 2012)

Form of Award Notice (Filed With SEC on November 6, 2012)

FIFTH AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009 (Filed With SEC on November 6, 2012)

FOURTH AMENDMENT TO THE AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009 (Filed With SEC on November 6, 2012)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on September 13, 2012)

FOURTH AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009 (Filed With SEC on August 8, 2012)

THIRD AMENDMENT TO THE AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009 (Filed With SEC on August 8, 2012)

Form of Award Notice (Filed With SEC on August 8, 2012)

AMGEN INC. $1,250,000,000 2.125% SENIOR NOTES DUE 2017 $750,000,000 3.625% SENIOR NOTES DUE 2022 $1,000,000,000 5.375% SENIOR NOTES DUE2043 Underwriting Agreement (Filed With SEC on May 15, 2012)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on May 15, 2012)

Form of Award Notice (Filed With SEC on May 8, 2012)

AMGEN INC. 2009 PERFORMANCE AWARD PROGRAM (Effective March 3, 2009) As Amended March 14, 2012 ARTICLE I PURPOSE (Filed With SEC on May 8, 2012)

Form of Award Notice (Filed With SEC on May 8, 2012)

AMGEN INC. 2009 DIRECTOR EQUITY INCENTIVE PROGRAM (Effective March 3,2009) As Amended March 15, 2012 ARTICLE I PURPOSE (Filed With SEC on May 8, 2012)

24 April 2012 THE PERSONS LISTED IN PART 3 OF SCHEDULE 1 AS MN SELLERS (as defined herein) and THE PERSONS LISTED IN PART 5 OF SCHEDULE 1 AS SIHHAT SELLERS (as defined herein) and... (Filed With SEC on April 30, 2012)

CONSULTING SERVICES AGREEMENT (Filed With SEC on March 1, 2012)

SECOND AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009 (Filed With SEC on February 29, 2012)

THIRD AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009 (Filed With SEC on February 29, 2012)

SECOND AMENDMENT TO THE AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009 (Filed With SEC on February 29, 2012)

AGREEMENT AND PLAN OF MERGER among: MICROMET, INC., a Delaware corporation; AMGEN INC., a Delaware corporation; and ARMSTRONG ACQUISITION CORP., a Delaware corporation Dated as of... (Filed With SEC on January 26, 2012)

CREDIT AGREEMENT Dated as of December 2, 2011 among Amgen Inc., The Borrowing Subsidiaries Herein Named, The Banks Herein Named, Citibank, N.A., as Administrative Agent, and... (Filed With SEC on December 5, 2011)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on December 5, 2011)

AMGEN INC. $1,000,000,000 1.875% SENIOR NOTES DUE 2014 $1,000,000,000 2.50% SENIOR NOTES DUE 2016 $1,750,000,000 3.875% SENIOR NOTES DUE 2021 $2,250,000,000 5.15% SENIOR NOTES... (Filed With SEC on November 10, 2011)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on November 10, 2011)

Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange... (Filed With SEC on November 4, 2011)

AMENDMENT NUMBER 3 TO THEINTEGRATED FACILITIES MANAGEMENT SERVICES AGREEMENT BETWEEN JONES LANG LASALLE AMERICAS, INC. AND AMGEN INC. (Filed With SEC on November 4, 2011)

EX-101 INSTANCE DOCUMENT (Filed With SEC on August 8, 2011)

AMGEN INC. $750,000,000 2.30% SENIOR NOTES DUE 2016 $1,000,000,000 4.10% SENIOR NOTES DUE 2021 $1,250,000,000 5.65% SENIOR NOTES DUE 2042 Underwriting Agreement (Filed With SEC on June 30, 2011)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on June 30, 2011)

EX-101 INSTANCE DOCUMENT (Filed With SEC on May 10, 2011)

AMGEN INC. CHANGE OF CONTROL SEVERANCE PLAN (Filed With SEC on December 15, 2010)

EX-101 INSTANCE DOCUMENT (Filed With SEC on November 8, 2010)

CONSULTING SERVICES AGREEMENT (Filed With SEC on October 22, 2010)

AMGEN INC. $900,000,000 3.45% SENIOR NOTES DUE 2020 $600,000,000 4.95% SENIOR NOTES DUE 2041 Underwriting Agreement (Filed With SEC on September 17, 2010)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on September 17, 2010)

EX-31 SECTION 302 CERTIFICATIONS (Filed With SEC on August 9, 2010)

Form of Award Notice (Filed With SEC on May 7, 2010)

AMGEN INC. (Filed With SEC on March 12, 2010)

OFFICERS CERTIFICATE OF (Filed With SEC on March 12, 2010)

Form of Award Notice (Filed With SEC on March 1, 2010)

AMGEN INC. 2009 PERFORMANCE AWARD PROGRAM (Effective March 3, 2009) ARTICLE I PURPOSE (Filed With SEC on March 1, 2010)

Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange... (Filed With SEC on March 1, 2010)

Form of Award Notice (Filed With SEC on November 6, 2009)

AMGEN INC. 2009 PERFORMANCE AWARD PROGRAM (Effective March 3, 2009) ARTICLE I PURPOSE (Filed With SEC on November 6, 2009)

Form of Award Notice (Filed With SEC on November 6, 2009)

Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange... (Filed With SEC on November 6, 2009)

AMENDMENT NO. 1 TO CREDIT AGREEMENT (Filed With SEC on August 10, 2009)

AMENDMENT NO. 7 TO THE ENBREL SUPPLY AGREEMENT (Filed With SEC on May 11, 2009)

Form of Award Notice (Filed With SEC on May 8, 2009)

AMGEN INC. 2009 PERFORMANCE AWARD PROGRAM (Filed With SEC on May 8, 2009)

Form of Award Notice (Filed With SEC on May 8, 2009)

AMGEN INC. 2009 DIRECTOR EQUITY INCENTIVE PROGRAM (Effective March 3, 2009) (Filed With SEC on May 8, 2009)

GRANT OF NON-QUALIFIED STOCK OPTION (Director Equity Incentive Program) (Filed With SEC on May 8, 2009)

RESTRICTED STOCK UNIT AGREEMENT (Director Equity Incentive Program) (Filed With SEC on May 8, 2009)

GRANT OF NONQUALIFIED STOCK OPTION (EX-U.S.) (Filed With SEC on February 27, 2009)

AMENDMENT AND RESTATEMENT OF THE AMGEN CHANGE OF CONTROL SEVERANCE PLAN (Filed With SEC on February 27, 2009)

MASTER SERVICES AGREEMENT (Filed With SEC on February 27, 2009)

INTEGRATED FACILITIES MANAGEMENT SERVICES AGREEMENT (Filed With SEC on February 27, 2009)

AMGEN INC. $1,000,000,000 5.70% SENIOR NOTES DUE 2019 $1,000,000,000 6.40% SENIOR NOTES DUE 2039 Underwriting Agreement (Filed With SEC on January 16, 2009)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on January 16, 2009)

AMGEN INC. AMENDED AND RESTATED 1991 EQUITY INCENTIVE PLAN (Filed With SEC on November 7, 2008)

AMGEN INC. AMENDED AND RESTATED 1999 EQUITY INCENTIVE PLAN (Filed With SEC on November 7, 2008)

AMGEN INC. AMENDED AND RESTATED 1999 INCENTIVE STOCK PLAN (Filed With SEC on November 7, 2008)

GRANT OF STOCK OPTION AGREEMENT (Filed With SEC on November 7, 2008)

AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN (Filed With SEC on November 7, 2008)

AMGEN INC. EXECUTIVE INCENTIVE PLAN (Filed With SEC on November 7, 2008)

AMGEN INC. EXECUTIVE NONQUALIFIED RETIREMENT PLAN (Filed With SEC on November 7, 2008)

As Amended and Restated Effective January 1, 2009 (Filed With SEC on November 7, 2008)

AMENDED AND RESTATED AMGEN INC. PERFORMANCE AWARD PROGRAM (Filed With SEC on November 7, 2008)

AMENDMENT NO. 2 TO AMENDMENT NO. 6 TO THE ENBREL® SUPPLY AGREEMENT (Filed With SEC on November 7, 2008)

AMENDMENT NO. 1 TO AMENDMENT NO. 2 TO THE (Filed With SEC on August 8, 2008)

VARIABLE TERM ACCELERATED SHARE REPURCHASE TRANSACTION (Filed With SEC on August 8, 2008)

AMGEN INC. $500,000,000 6.15% SENIOR NOTES DUE 2018 $500,000,000 6.90% SENIOR NOTES DUE 2038 Underwriting Agreement (Filed With SEC on May 23, 2008)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on May 23, 2008)

FIFTH AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN (Filed With SEC on May 12, 2008)

AMENDED AND RESTATED AMGEN INC. PERFORMANCE AWARD PROGRAM (Filed With SEC on May 12, 2008)

Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange... (Filed With SEC on May 12, 2008)

RECITALS: (Filed With SEC on February 28, 2008)

GRANT OF STOCK OPTION (Filed With SEC on February 28, 2008)

AMGEN INC. AMENDED AND RESTATED DIRECTOR EQUITY INCENTIVE PROGRAM (Amended and Restated EffectiveDecember 10, 2007) ARTICLE I PURPOSE (Filed With SEC on February 28, 2008)

SECOND AMENDMENT TO THE AMGEN INC. AMENDED AND RESTATED (Filed With SEC on February 28, 2008)

FIFTH AMENDMENT TO THE AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN (Filed With SEC on February 28, 2008)

AMENDMENT NO. 6 TO THE (Filed With SEC on February 28, 2008)

AMENDED AND RESTATED AMGEN INC. PERFORMANCE AWARD PROGRAM (Filed With SEC on December 13, 2007)

FOURTH AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN (Filed With SEC on November 9, 2007)

FIRST AMENDMENT TO THE AMGEN INC. EXECUTIVE (Filed With SEC on November 9, 2007)

FOURTH AMENDMENT TO THE AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN (Filed With SEC on November 9, 2007)

AMENDMENT TO PROMISSORY NOTE (Filed With SEC on November 9, 2007)

Collaboration Agreement By and Between Amgen Inc. and Daiichi Sankyo Company, Limited (Filed With SEC on November 9, 2007)

CREDIT AGREEMENT Dated as of November 2, 2007 (Filed With SEC on November 2, 2007)

AMGEN INC. DIRECTOR EQUITY INCENTIVE PROGRAM (Filed With SEC on August 9, 2007)

AMENDED AND RESTATED AMGEN INC. PERFORMANCE AWARD PROGRAM (Filed With SEC on August 9, 2007)

PERFORMANCE UNIT AGREEMENT (Filed With SEC on August 9, 2007)

AMENDMENT NO. 13 TO THE SHAREHOLDERS AGREEMENT OF KIRIN-AMGEN, INC. (Filed With SEC on August 9, 2007)

PURCHASE AGREEMENT Dated May 24, 2007 between AMGEN INC. (Filed With SEC on August 9, 2007)

PURCHASE AGREEMENT (Filed With SEC on August 9, 2007)

OFFICERS CERTIFICATE OF AMGEN INC. (Filed With SEC on May 30, 2007)

REGISTRATION RIGHTS AGREEMENT between AMGEN INC. and MORGAN STANLEY & CO. INCORPORATED and (Filed With SEC on May 30, 2007)

THIRD AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN (Filed With SEC on February 28, 2007)

EIGHTH AMENDMENT TO THE AMGEN INC. CHANGE OF CONTROL SEVERANCE PLAN (Filed With SEC on February 28, 2007)

THIRD AMENDMENT TO THE AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN (Filed With SEC on February 28, 2007)

FOURTH AMENDMENT TO THE AMGEN RETIREMENT AND SAVINGS PLAN (Filed With SEC on October 6, 2006)

SEVENTH AMENDMENT TO THE AMGEN INC. CHANGE OF CONTROL SEVERANCE PLAN (Filed With SEC on October 6, 2006)

AGREEMENT AND PLAN OF MERGER BY AND AMONG AMGEN INC., AVIATOR MERGER SUB, INC., AVIDIA, INC. (Filed With SEC on October 2, 2006)

THIRD AMENDMENT TO THE AMGEN RETIREMENT AND SAVINGS PLAN (Filed With SEC on September 15, 2006)

AMGEN INC. $2,500,000,000 0.125% Convertible Senior Notes due 2011 INDENTURE Dated as of February 17, 2006 JPMORGAN CHASE BANK, N.A., Trustee (Filed With SEC on August 9, 2006)

AMGEN INC. $2,500,000,000 0.375% Convertible Senior Notes due 2013 INDENTURE Dated as of February 17, 2006 JPMORGAN CHASE BANK, N.A., Trustee (Filed With SEC on August 9, 2006)

AMENDMENT TO THE AMENDED AND RESTATED RIGHTS AGREEMENT (Filed With SEC on July 14, 2006)

SECOND AMENDMENT TO THE AMGEN RETIREMENT AND SAVINGS PLAN (Filed With SEC on July 14, 2006)

FIRST AMENDMENT TO THE AMGEN RETIREMENT AND SAVINGS PLAN (Filed With SEC on May 16, 2006)

SECOND AMENDMENT TO THE AMGEN SUPPLEMENTAL RETIREMENT PLAN (Filed With SEC on May 16, 2006)

SIXTH AMENDMENT TO THE AMGEN INC. CHANGE OF CONTROL SEVERANCE PLAN (Filed With SEC on May 16, 2006)

RESTRICTEDSTOCK PURCHASE AGREEMENT (Filed With SEC on March 10, 2006)

PURCHASE AGREEMENT (Filed With SEC on March 10, 2006)

AMGEN INC. $2,500,000,000 0.125% Convertible Senior Notes due 2011 INDENTURE Dated as of February 17, 2006 JPMORGAN CHASE BANK, N.A., Trustee CROSS REFERENCE TABLE* (Filed With SEC on February 21, 2006)

AMGEN INC. $2,500,000,000 0.375% Convertible Senior Notes due 2013 INDENTURE (Filed With SEC on February 21, 2006)

Registration RightsAgreement Dated As of February 17, 2006 between (Filed With SEC on February 21, 2006)

Purchase Agreement Dated February 14, 2006 (Filed With SEC on February 21, 2006)

AGREEMENT AND PLAN OFMERGER Among Abgenix, Inc., Amgen Inc. and Athletics Merger Sub,Inc. Dated as of December 14,2005 (Filed With SEC on December 15, 2005)

AMGEN INC. (Filed With SEC on December 8, 2005)

AMENDED AND RESTATED AMGEN INC. PERFORMANCE AWARD PROGRAM (Amended and Restated Effective December 5, 2005) (Filed With SEC on December 8, 2005)

GRANT OF STOCKOPTION (Filed With SEC on December 8, 2005)

PERFORMANCE UNIT AGREEMENT (Filed With SEC on December 8, 2005)

AMGEN INC. DIRECTOR EQUITY INCENTIVE PROGRAM (Amended and Restated Effective December 6, 2005) (Filed With SEC on December 8, 2005)

RESTRICTED STOCK UNIT AGREEMENT (Filed With SEC on December 8, 2005)

AMGEN INC. (Filed With SEC on December 8, 2005)

SECOND AMENDMENT TO THE AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN (As Amended and Restated Effective January 1,2005) (Filed With SEC on November 22, 2005)

Three Months Ended (Filed With SEC on November 9, 2005)

AMGEN RETIREMENT AND SAVINGS PLAN (As Amended and Restated Effective January 1, 2006) TABLE OF CONTENTS (Filed With SEC on October 20, 2005)

FIRST AMENDMENT TO THE AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2005 (Filed With SEC on October 20, 2005)

FIRST AMENDMENT TO THE AMGEN SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2005 (Filed With SEC on October 20, 2005)

GRANT OF STOCKOPTION (Filed With SEC on October 20, 2005)

Three Months Ended (Filed With SEC on August 8, 2005)

FIRST AMENDMENT TO THE AMGEN INC. AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on July 14, 2005)

Three Months Ended (Filed With SEC on May 4, 2005)

Our annual report on Form 10-K for the fiscal year ended December 31, 2004 (Filed With SEC on March 14, 2005)

AMGEN INC. (Filed With SEC on March 11, 2005)

AMGEN INC. AMENDEDAND RESTATED 1999 EQUITY INCENTIVE PLAN (Filed With SEC on March 11, 2005)

AMENDED AND RESTATED AMGEN INC. PERFORMANCE AWARD PROGRAM (Amended and Restated Effective March 7, 2005) (Filed With SEC on March 11, 2005)

GRANT OF STOCKOPTION (Filed With SEC on March 11, 2005)

PERFORMANCE UNIT AGREEMENT (Filed With SEC on March 11, 2005)

EPOGEN (Epoetin alfa) (Filed With SEC on March 9, 2005)

AMGEN INC. Liquid Yield Option Notes due 2032 (Zero Coupon Senior) (Filed With SEC on March 4, 2005)

FOURTH AMENDMENT TO THE AMGEN RETIREMENT AND SAVINGS PLAN (AS AMENDED AND RESTATED EFFECTIVE AS OF JANUARY 1, 2003) (Filed With SEC on December 9, 2004)

FIFTH AMENDMENT TO THE AMGEN INC. CHANGE OF CONTROL SEVERACE PLAN (Filed With SEC on December 9, 2004)

FIRST AMENDMENT TO THE AMGEN INC. EXECUTIVE INCENTIVE PLAN (Filed With SEC on December 9, 2004)

AMGEN INC. AMENDED AND RESTATED 1991 EQUITY INCENTIVE PLAN (Filed With SEC on December 9, 2004)

AMGEN INC. PERFORMANCE AWARD PROGRAM (Amended and Restated Effective December 6, 2004) (Filed With SEC on December 9, 2004)

FORM OF PERFORMANCE UNIT AGREEMENT (Filed With SEC on December 9, 2004)

AMGEN INC. DIRECTOR EQUITY INCENTIVE PROGRAM (Amended and Restated Effective December 6, 2004) (Filed With SEC on December 9, 2004)

Exhibit No (Filed With SEC on November 19, 2004)

Three Months Ended (Filed With SEC on November 9, 2004)

THIRD AMENDMENT TO THE AMGEN RETIREMENT AND SAVINGS PLAN (AS AMENDED AND RESTATED EFFECTIVE AS OF JANUARY 1, 2003) (Filed With SEC on October 12, 2004)

AMGEN INC. SUPPLEMENTAL (Filed With SEC on October 12, 2004)

Three Months Ended (Filed With SEC on August 6, 2004)

AMGEN INC. (Filed With SEC on April 26, 2004)

AGREEMENT AND PLAN OF MERGER BY AND AMONG AMGEN INC., ARROW ACQUISITION, LLC AND TULARIK INC. (Filed With SEC on March 29, 2004)

STOCKHOLDER VOTING AGREEMENT BY AND BETWEEN AMGEN INC. (Filed With SEC on March 29, 2004)

AMENDED AND RESTATED 1997 SPECIAL NON-OFFICER EQUITY INCENTIVE PLAN (Filed With SEC on July 30, 2003)

RESTRICTED STOCK PURCHASE AGREEMENT (Filed With SEC on July 30, 2003)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 10, 2003)

AMENDMENT NO. 3 TO THE (Filed With SEC on March 10, 2003)

THE AMGEN 1999 UK COMPANY EMPLOYEE SHARE OPTIONPLAN (Filed With SEC on March 10, 2003)

RESTRICTED STOCK PURCHASE AGREEMENT (Filed With SEC on March 10, 2003)

AMGEN INC. AMENDED AND RESTATED 1991 EQUITY INCENTIVE PLAN (Filed With SEC on November 5, 2002)

AMGEN INC. AMENDED AND RESTATED 1997 SPECIAL NON-OFFICER EQUITY INCENTIVE PLAN (Filed With SEC on November 5, 2002)

2002 SPECIAL SEVERANCE PAY PLAN FOR AMGEN EMPLOYEES (Filed With SEC on August 13, 2002)

AMENDMENT NO. 2 TO THE ENBREL® SUPPLY AGREEMENT (Filed With SEC on August 13, 2002)

ASSET PURCHASE AGREEMENT by and between Immunex Corporation as Seller, and Schering Aktiengesellschaft (Filed With SEC on August 13, 2002)

AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT (Filed With SEC on August 13, 2002)

AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT (Filed With SEC on August 13, 2002)

PROMISSORY NOTE (Filed With SEC on August 13, 2002)

Date Number of Shares for WhichRepurchase Option Shall Lapse Grant Date 34,000 First Anniversary of Grant Date 33,000 Second Anniversary of Grant Date 33,000 (Filed With SEC on August 13, 2002)

GRANT OF STOCK OPTION (Filed With SEC on August 13, 2002)

PROMISSORY NOTE $500,000.00 (Filed With SEC on August 13, 2002)

Category

Industry

Companies

Contracts

Amgen Inc. Contracts & Agreements